Suomi - suomi - Fimea (Suomen lääkevirasto)

ratiopharm gmbh - valsartanum - tabletti, kalvopäällysteinen - 80 mg - valsartaani

Suomi - suomi - Fimea (Suomen lääkevirasto)

ratiopharm gmbh - valsartanum - tabletti, kalvopäällysteinen - 160 mg - valsartaani

Suomi - suomi - Fimea (Suomen lääkevirasto)

ratiopharm gmbh - hydrochlorothiazidum,valsartanum - tabletti, kalvopäällysteinen - 80 mg / 12.5 mg - valsartaani ja diureetit

Suomi - suomi - Fimea (Suomen lääkevirasto)

ratiopharm gmbh - valsartanum,hydrochlorothiazidum - tabletti, kalvopäällysteinen - 160 mg / 12.5 mg - valsartaani ja diureetit

Suomi - suomi - Fimea (Suomen lääkevirasto)

ratiopharm gmbh - hydrochlorothiazidum,valsartanum - tabletti, kalvopäällysteinen - 160 mg / 25 mg - valsartaani ja diureetit

Suomi - suomi - Fimea (Suomen lääkevirasto)

ratiopharm gmbh - valsartanum - tabletti, kalvopäällysteinen - 320 mg - valsartaani

Suomi - suomi - Fimea (Suomen lääkevirasto)

medice arzneimittel pütter gmbh & co. kg - cinacalcetum hydrochloridum - tabletti, kalvopäällysteinen - 90 mg - sinakalseetti

Euroopan unioni - suomi - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic acid, metformin hydrochloride - diabetes mellitus, tyyppi 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated dose of metformin alonein patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetesin patients already being treated with the combination of ertugliflozin and metformin as separate tablets.

Euroopan unioni - suomi - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Suomi - suomi - Fimea (Suomen lääkevirasto)

stada arzneimittel ag - metformin hydrochloride, sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 50 mg / 1000 mg - metformiini ja sitagliptiini